amantadine has been researched along with Guillain-Barre Syndrome in 9 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Guillain-Barre Syndrome: An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amantadine was not superior to placebo." | 6.72 | Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006) |
| " The effects of amantadine from one randomised, double-blind, placebo-controlled, cross-over trial comparing amantadine with placebo for the treatment of fatigue in 80 people with Guillain-Barré syndrome (GBS) were uncertain for the proportion of people achieving a favourable outcome six weeks post-intervention (odds ratio (OR) 0." | 4.90 | Interventions for fatigue in peripheral neuropathy. ( Garssen, MP; Stockley, RC; van Doorn, PA; White, CM, 2014) |
| "The most common subtypes of GBS are acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN)." | 2.82 | Triggers of Guillain-Barré Syndrome: ( Finsterer, J, 2022) |
| "Amantadine was not superior to placebo." | 2.72 | Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006) |
| "The final subtype diagnosis was acute inflammatory demyelinating polyneuropathy (AIDP) in 16 patients (six met the criteria at the initial EDx study and 10 at follow-up) and acute motor axonal neuropathy (AMAN) in 10 patients (six initially)." | 1.91 | Identical late motor responses in early Guillain-Barré syndrome: A-waves and repeater F-waves. ( Chroni, E; Kefalopoulou, Z; Kintos, V; Veltsista, D, 2023) |
| "Several reports of RCF in acute inflammatory demyelinating polyneuropathy (AIDP) have suggested that it could be a manifestation of nodopathy." | 1.72 | Reversible conduction failure in acute inflammatory demyelinating polyneuropathy. ( Kim, S; Lee, EK; Sohn, E, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kalita, J | 1 |
| Misra, UK | 1 |
| Chaudhary, SK | 1 |
| Das, M | 1 |
| Mishra, A | 1 |
| Ranjan, A | 1 |
| Kumar, M | 1 |
| Kim, S | 2 |
| Lee, EK | 2 |
| Sohn, E | 2 |
| Finsterer, J | 3 |
| Veltsista, D | 3 |
| Kefalopoulou, Z | 3 |
| Kintos, V | 3 |
| Chroni, E | 3 |
| Jo, N | 1 |
| Agarwal, E | 1 |
| Bhagat, A | 1 |
| Srivastava, K | 1 |
| Thakore, B | 1 |
| Jagtap, S | 1 |
| Kalane, U | 1 |
| Rajadhyaksha, S | 1 |
| Gupta, J | 1 |
| Jauhari, P | 1 |
| White, CM | 1 |
| van Doorn, PA | 2 |
| Garssen, MP | 2 |
| Stockley, RC | 1 |
| Schmitz, PI | 1 |
| Merkies, IS | 1 |
| Jacobs, BC | 1 |
| van der Meché, FG | 1 |
3 reviews available for amantadine and Guillain-Barre Syndrome
| Article | Year |
|---|---|
Triggers of Guillain-Barré Syndrome:
Topics: Amantadine; Autoantibodies; Axons; Campylobacter jejuni; Guillain-Barre Syndrome; Humans | 2022 |
Triggers of Guillain-Barré Syndrome:
Topics: Amantadine; Autoantibodies; Axons; Campylobacter jejuni; Guillain-Barre Syndrome; Humans | 2022 |
Triggers of Guillain-Barré Syndrome:
Topics: Amantadine; Autoantibodies; Axons; Campylobacter jejuni; Guillain-Barre Syndrome; Humans | 2022 |
Triggers of Guillain-Barré Syndrome:
Topics: Amantadine; Autoantibodies; Axons; Campylobacter jejuni; Guillain-Barre Syndrome; Humans | 2022 |
Triggers of Guillain-Barré Syndrome:
Topics: Amantadine; Autoantibodies; Axons; Campylobacter jejuni; Guillain-Barre Syndrome; Humans | 2022 |
Triggers of Guillain-Barré Syndrome:
Topics: Amantadine; Autoantibodies; Axons; Campylobacter jejuni; Guillain-Barre Syndrome; Humans | 2022 |
Triggers of Guillain-Barré Syndrome:
Topics: Amantadine; Autoantibodies; Axons; Campylobacter jejuni; Guillain-Barre Syndrome; Humans | 2022 |
Triggers of Guillain-Barré Syndrome:
Topics: Amantadine; Autoantibodies; Axons; Campylobacter jejuni; Guillain-Barre Syndrome; Humans | 2022 |
Triggers of Guillain-Barré Syndrome:
Topics: Amantadine; Autoantibodies; Axons; Campylobacter jejuni; Guillain-Barre Syndrome; Humans | 2022 |
How Important it is to Differentiate AMAN from AIDP in Childhood GBS? A Clinician's Perspective.
Topics: Amantadine; Child; Guillain-Barre Syndrome; Humans; India; Prospective Studies | 2019 |
Interventions for fatigue in peripheral neuropathy.
Topics: Adult; Amantadine; Ascorbic Acid; Charcot-Marie-Tooth Disease; Child; Fatigue; Guillain-Barre Syndro | 2014 |
1 trial available for amantadine and Guillain-Barre Syndrome
| Article | Year |
|---|---|
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Anxiety; Cross-Over Studies; Depressio | 2006 |
5 other studies available for amantadine and Guillain-Barre Syndrome
| Article | Year |
|---|---|
Outcome of Guillain-Barré syndrome following intravenous immunoglobulin compared to natural course.
Topics: Amantadine; Guillain-Barre Syndrome; Hospital Mortality; Humans; Immunoglobulins, Intravenous; Respi | 2022 |
Reversible conduction failure in acute inflammatory demyelinating polyneuropathy.
Topics: Amantadine; Gangliosides; Guillain-Barre Syndrome; Heart Rate; Humans; Neural Conduction | 2022 |
Identical late motor responses in early Guillain-Barré syndrome: A-waves and repeater F-waves.
Topics: Amantadine; Guillain-Barre Syndrome; Humans; Neural Conduction; Retrospective Studies | 2023 |
Identical late motor responses in early Guillain-Barré syndrome: A-waves and repeater F-waves.
Topics: Amantadine; Guillain-Barre Syndrome; Humans; Neural Conduction; Retrospective Studies | 2023 |
Identical late motor responses in early Guillain-Barré syndrome: A-waves and repeater F-waves.
Topics: Amantadine; Guillain-Barre Syndrome; Humans; Neural Conduction; Retrospective Studies | 2023 |
Identical late motor responses in early Guillain-Barré syndrome: A-waves and repeater F-waves.
Topics: Amantadine; Guillain-Barre Syndrome; Humans; Neural Conduction; Retrospective Studies | 2023 |
Association between hyperCKemia and axonal degeneration in Guillain-Barré syndrome.
Topics: Amantadine; Axons; Guillain-Barre Syndrome; Hospitalization; Humans; Nerve Conduction Studies; Retro | 2023 |
Clinical and Electrophysiological Factors Predicting Prolonged Recovery in Children with Guillain-Barré Syndrome.
Topics: Amantadine; Child; Guillain-Barre Syndrome; Humans; Neural Conduction; Neurologic Examination; Progn | 2022 |